Cimetidine tablets

This product is a histamine H2 receptor antagonist that has the effect of inhibiting gastric acid secretion. Its acid-suppressing effect is strong and can effectively inhibit basal gastric acid secretion and gastric acid secretion caused by various reasons such as food, histamine, pentapeptide gastrin, caffeine and insulin, etc., so as to reduce the amount and acidity of secretion, and can prevent or reduce the corrosive damage of gastric mucosa caused by bile salts, alcohol, aspirin and other non-steroidal anti-inflammatory drugs. It also has obvious therapeutic effects on stress ulcers and upper gastrointestinal bleeding. In addition, this product has anti-androgen effect and has certain value in the treatment of hirsutism; it can also weaken the activity of immunosuppressive cells, enhance immune response, thereby inhibiting tumor metastasis and prolonging survival. According to foreign data, this product can also effectively treat acute intermittent porphyria. Histamine activates adenylate cyclase by exciting H2 receptors to increase the production of cAMP in gastric parietal cells. cAMP activates carbonic anhydrase through protein kinase to catalyze CO2 and H2O to produce H2CO3 and further dissociate to release H, which increases gastric acid secretion. Cimetidine mainly acts on H2 receptors on parietal cells to competitively inhibit histamine and thus inhibit gastric acid secretion. This product has a significant effect of inhibiting gastric acid secretion. It can significantly inhibit basal and nocturnal gastric acid secretion. It can also inhibit gastric acid secretion caused by stimulation such as histamine, peptide, gastrin, insulin and food and reduce its acidity. It has a preventive and protective effect on corrosive gastritis caused by chemical stimulation, and also has a significant therapeutic effect on liquid gastric ulcer and upper gastrointestinal bleeding.

The main ingredient of this product is cimetidine. Its chemical name is N-methyl-N-[2[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]-N-cyanoguanidine.

This product is a white tablet or a light blue or light green tablet with a colorant, or a film-coated tablet.

Histamine H2 receptor blocker. Used to relieve stomach pain, heartburn, and acid reflux caused by excessive gastric acid; used to treat duodenal ulcer, gastric ulcer, upper gastrointestinal bleeding and Zollinger-Ellison syndrome.

Oral administration. Adults: 1 tablet at a time, 2 times a day, not more than 4 times in 24 hours. (1) For the treatment of duodenal ulcer or pathological hypersecretion, 0.2-0.4g at a time, 4 times a day, after meals and before bedtime, or 0.8g at a time, once before bedtime. (2) To prevent recurrence of ulcer, 0.4g at a time, before bedtime; (3) For patients with renal insufficiency, the dosage is reduced to 0.2g at a time, once every 12 hours. (4) For elderly patients, the dosage is reduced as appropriate. (5) For children: Oral administration, 5-10mg/kg per body weight, 2-4 times a day.

1 Long-term use or increased dosage may cause: male breast swelling, lactation, loss of libido, diarrhea, dizziness or headache, muscle cramps or myalgia, rash, hair loss, etc. 2 Occasional adverse reactions include: (1) mental disorder, which is more common in elderly or seriously ill patients and can be recovered within 48 hours after stopping the drug; (2) sore throat and fever; (3) unexplained bleeding or ecchymosis, as well as abnormal fatigue and weakness; (4) granulocytopenia or other abnormal blood counts, which are more common in patients with serious complications.

Pregnant and lactating women are prohibited from using this product. People who are allergic to this product are prohibited from using this product.

Precautions for children: Children should use the product under the guidance of a physician. Precautions for pregnancy and lactation: Pregnant and lactating women are prohibited. Precautions for the elderly: Elderly patients should use the product under the guidance of a physician.

When used in combination with warfarin, theophylline, phenytoin and other drugs, the dosage should be reduced. Antacids such as aluminum hydroxide or metoclopramide can reduce the absorption of this product and reduce the effects of sucralfate, tetracycline and other drugs. When used in combination with opioids, patients with chronic renal failure may experience respiratory depression, mental confusion and disorientation, etc. The dosage of opioid preparations should be reduced. 1. This product is a liver drug enzyme inhibitor. It reduces the activity of drug enzymes by binding to cytochrome P450 through its imidazole ring. It can also reduce liver blood flow. Therefore, when this product is used in combination with propranolol, the latter's blood concentration can be increased and the heart rate at rest can be slowed down; when used in combination with phenytoin sodium or other hydantoins, the latter's blood concentration can be increased, which may lead to phenytoin sodium poisoning. If it must be used in combination, the blood concentration of phenytoin sodium should be measured after 5 days in order to adjust the dosage; 2. When this product is used in combination with cyclosporine, the latter 3. When this product is used in combination with moclobemide, the latter's blood concentration can be increased; 4. When this product is used in combination with aspirin, the solubility of aspirin can be increased and the absorption can be enhanced; 5. When this product is used in combination with methadone, the latter's blood concentration can be increased, which may lead to the risk of overdose; 6. When this product is used in combination with tacrine, the latter's blood concentration can be increased, which may lead to the risk of overdose; 7. When this product is used in combination with benzodiazepines (such as diazepam, nitrazepam, flunitrazepam, chlordiazepoxide, midazolam, triazole When used in combination with dapoxetine, oxazepam, temazepam, etc., it can inhibit the latter's liver metabolism, increase its blood concentration, aggravate its sedation and other central nervous system depression symptoms, and develop into respiratory and circulatory failure. However, lorazepam, oxazepam and temazepam seem to be unaffected; 8 When this product is used in combination with coumarin anticoagulants, it can reduce the latter's excretion rate from the body and further prolong the prothrombin time, thereby leading to bleeding tendency. When using both, it is necessary to pay close attention to changes in the condition and adjust the dosage of anticoagulants; 9 This product can increase the absolute bioavailability of verapamil (Isapamil). Although verapamil can cause serious adverse reactions, although rare, it should still be paid attention to; 10 When this product is used in combination with theophylline, it can reduce the latter's demethylation metabolic clearance rate by 20-30% and increase its blood concentration; 11 Patients taking digoxin and quinidine should not use this product together because this product can inhibit the metabolism of quinidine, and the latter can displace digoxin from its binding site, resulting in increased blood concentrations of quinidine and digoxin; 1 2. When this product is used in combination with carbamazepine, it can increase the latter's blood concentration, which may lead to the risk of overdose; 13. When this product is used in combination with lidocaine (extra-gastrointestinal medication), it can increase the latter's blood concentration, thereby increasing the risk of adverse reactions to the nervous system and heart. When the two are used in combination, the lidocaine dose needs to be adjusted and clinical monitoring needs to be strengthened; 14. When this product is used in combination with caffeine, it can delay the metabolism of caffeine, enhance its effect, and easily cause toxic reactions. Patients with gastric ulcers should avoid caffeine and should not use caffeine and caffeinated beverages when taking this product; 15. When this product is used in combination with antacids (such as aluminum hydroxide and magnesium oxide), it can relieve the pain of duodenal ulcers, but the absorption of cimetidine may be reduced. Therefore, it is generally not recommended to use the two together. If they must be used together, they should be taken at least 1 hour apart; 16. When used in combination with metoclopramide, the blood concentration of this product can be reduced. If they need to be used together, the dose of this product should be appropriately increased; 17. Sucralfate needs to be hydrolyzed by gastric acid to take effect, and this product inhibits gastric acid. Acid secretion, so the efficacy of sucralfate may be reduced when the two are used together; 18 This product increases the pH value of gastric juice. When used in combination with tetracycline, it can reduce the dissolution rate of tetracycline and weaken the absorption reduction effect; but the hepatic enzyme inhibition of this product may increase the blood concentration of tetracycline; 19 This product can interfere with the absorption of ketoconazole and reduce its antifungal activity when used in combination with ketoconazole, but the above changes can be avoided by taking some acidic beverages at the same time; 20 This product may cause psychotic symptoms when used in combination with captopril; 21 This product has a neuromuscular blocking effect similar to that of aminoglycosides, so it may cause respiratory depression or respiratory arrest when used in combination with aminoglycoside antibiotics; 22 This product should be avoided from being used simultaneously with central anticholinergics to prevent aggravation of central nervous system toxicity; 23 When used in combination with carmustine, it can increase bone marrow toxicity; 24 When this product is used in combination with opioids, there are reports of adverse reactions such as respiratory depression, mental confusion, and disorientation in patients with chronic renal failure.

Keep sealed.

0.8 g

36 months

Jiangxi Pharmaceutical Co., Ltd.

• Founded in:

  1996-06-10

• Address:

  No. 758, Huiren West Avenue, Xiaolan Industrial Park, Nanchang County, Nanchang City, Jiangxi Province

• Tax NO.:

  913600001582615429

• Registered Funds:

  295.8 million yuan

• Website:

  Log in to view

• Email:

  Log in to view